- Home
- TLSA vs CLYM Comparison
TLSA vs CLYM Comparison
Compare TLSA & CLYM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TLSA
- CLYM
- Stock Information
- Founded
- TLSA 2013
- CLYM 2018
- Country
- TLSA United Kingdom
- CLYM United States
- Employees
- TLSA N/A
- CLYM N/A
- Industry
- TLSA Biotechnology: Pharmaceutical Preparations
- CLYM
- Sector
- TLSA Health Care
- CLYM
- Exchange
- TLSA Nasdaq
- CLYM NYSE
- Market Cap
- TLSA 87.8M
- CLYM 101.6M
- IPO Year
- TLSA 2000
- CLYM 2021
- Fundamental
- Price
- TLSA $1.07
- CLYM $1.26
- Analyst Decision
- TLSA
- CLYM
- Analyst Count
- TLSA 0
- CLYM 0
- Target Price
- TLSA N/A
- CLYM N/A
- AVG Volume (30 Days)
- TLSA 363.4K
- CLYM 170.7K
- Earning Date
- TLSA 05-09-2025
- CLYM 05-14-2025
- Dividend Yield
- TLSA N/A
- CLYM N/A
- EPS Growth
- TLSA N/A
- CLYM N/A
- EPS
- TLSA N/A
- CLYM N/A
- Revenue
- TLSA N/A
- CLYM N/A
- Revenue This Year
- TLSA N/A
- CLYM N/A
- Revenue Next Year
- TLSA N/A
- CLYM N/A
- P/E Ratio
- TLSA N/A
- CLYM N/A
- Revenue Growth
- TLSA N/A
- CLYM N/A
- 52 Week Low
- TLSA $0.49
- CLYM $1.05
- 52 Week High
- TLSA $1.91
- CLYM $11.55
- Technical
- Relative Strength Index (RSI)
- TLSA 53.21
- CLYM N/A
- Support Level
- TLSA $0.76
- CLYM N/A
- Resistance Level
- TLSA $1.13
- CLYM N/A
- Average True Range (ATR)
- TLSA 0.11
- CLYM 0.00
- MACD
- TLSA -0.00
- CLYM 0.00
- Stochastic Oscillator
- TLSA 85.00
- CLYM 0.00
About TLSA Tiziana Life Sciences Ltd.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in the developing transformative therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, ALS. Alzheimer's, Crohn's Disease and KRAS+ NSCLC. Tiziana is led by a team of qualified executives with extensive drug development and commercialization experience.
About CLYM CLIMB BIO INC
Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its lead product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.